<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00799656</url>
  </required_header>
  <id_info>
    <org_study_id>DFI10569</org_study_id>
    <secondary_id>EudraCT 2008-001518-26</secondary_id>
    <nct_id>NCT00799656</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Ataciguat Versus Placebo in Patients With Neuropathic Pain</brief_title>
  <acronym>SERENEATI</acronym>
  <official_title>Efficacy and Safety of Oral Ataciguat (HMR1766) 200 mg Administered Once Daily for 28 Days on Pain Reduction in Patients With Neuropathic Pain. A Randomized, Double-blind, Placebo-controlled, Cross-over Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the efficacy of ataciguat versus placebo in
      reducing pain intensity in patients with neuropathic pain.

      The secondary objective is to assess the safety and tolerability of ataciguat versus placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study consists of two consecutive 28 day treatment periods which are separated by a 2
      week medication free period and a safety follow-up period of 2 weeks after the second
      treatment period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in average daily pain intensity</measure>
    <time_frame>after 28-days treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Responder rate</measure>
    <time_frame>after 28-days treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue medication intake</measure>
    <time_frame>during 28-days treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Neuropathic Pain Symptom Inventory (NPSI)</measure>
    <time_frame>after 28-days treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First period: Ataciguat - Second period: Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First period: Placebo - Second period: Ataciguat</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ataciguat (HMR1766)</intervention_name>
    <description>oral administration 200mg once daily for 28 days</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>oral administration once daily for 28 days</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with chronic neuropathic pain due to diabetic polyneuropathy or a nerve
             lesion following surgery. The pain must be present for more than 3 months.

        Exclusion Criteria:

          -  Presence or history of cancer within the past five years

          -  Patients with a history of HIV infection

          -  Patients with active hepatitis B or C

          -  Patients with any pain other than the neuropathic pain of greater or equal severity

          -  Patients with a diabetes mellitus for less than 6 months

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans-Goerg Kress, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medizinische Universität / AKH Wien - Währinger Gürtel 18-20 - A-1090 Wien</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Czech Republic</country>
    <country>Romania</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2008</study_first_submitted>
  <study_first_submitted_qc>November 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2008</study_first_posted>
  <last_update_submitted>March 31, 2011</last_update_submitted>
  <last_update_submitted_qc>March 31, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2011</last_update_posted>
  <responsible_party>
    <name_title>ICD Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <keyword>Diabetic neuropathy</keyword>
  <keyword>painful pain</keyword>
  <keyword>postoperative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

